Skip to main content
. 2015 Apr 14;21(14):4358–4364. doi: 10.3748/wjg.v21.i14.4358

Table 1.

Characteristics of trials included in meta-analysis

Study Patients (S-1/capecitabine) S-1 regimen Capecitabine regimen
Kim et al[23] 65/64 S-1 80 mg/m2 per day d1-14 + oxaliplatin 130 mg/m2 d1 21-d cycle Capecitabine 2000 mg/m2 per day d1-14 + oxaliplatin 130 mg/m2 d1 21-d cycle
Lee et al[22] 42/44 S-1: BSA < 1.25 m2, 80 mg/d; Capecitabine
BSA: 1.25-1.5 m2, 100 mg/d; 2500 mg/m2 per day
BSA > 1.5 m2, 120 mg/d; d1-28 42-d cycle d1-14 21-d cycle
Zhang et al[21] 41/40 S-1 80 mg/m2 per day d1-14 + oxaliplatin 130 mg/m2 d1 21-d cycle Capecitabine 2000 mg/m2 per day d1-14 + oxaliplatin 130 mg/m2 d1 21-d cycle
Xiong et al[20] 42/44 S-1 80 mg/m2 per day d1-14 + docetaxel 25 mg/m2 d1, 8, 15 28-d cycle Capecitabine 1250 mg/m2 per day d1-14 + docetaxel 25 mg/m2 d1, 8, 15 28-d cycle